 Home > Active Ingredient News > Drugs Articles > Novo Nordisk's "once a week" new diabetes drug is officially approved in China

Novo Nordisk's "once a week" new diabetes drug is officially approved in China

 Last Update: 2021-05-22
 Source: Internet
 Author: User

Tags

insulin patch diabetes

nicotine half life

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 29, Novo Nordisk issued a press release stating that the National Medical Products Administration (NMPA) has approved Novo Nordisk's research and development and production of Novotel® (Smeglutide Injection) in China for the listing application.

Novotel® (simeglutide injection) is a new long-acting glucagon-like peptide-1 (GLP-1) analogue of Novo Nordisk.

It is currently available in the United States, Europe, Canada, and Japan.
Approved for listing in 52 countries and regions.

Novotel® has a half-life of 7 days and is suitable for once a week injection with a stable blood concentration.

In January 2020, Novotel® cardiovascular indications were approved by the US FDA to reduce the risk of major cardiovascular events in adult patients with type 2 diabetes with cardiovascular disease.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.